-
公开(公告)号：US11771829B2
公开(公告)日：2023-10-03
申请号：US16778152
申请日：2020-01-31
申请人： Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc. , Novo Nordisk A/S
发明人： Robert S. Langer , Carlo Giovanni Traverso , Alex G. Abramson , Morten Revsgaard Frederiksen , Mikkel Oliver Jespersen , Brian Mouridsen , Jesper Windum , Mette Poulsen , Brian Jensen , Jorrit Jeroen Water , Mikkel Wennemoes Hvitfeld Ley , Xiaoya Lu , Andreas Vegge
CPC分类号： A61M5/2033 , A61K9/0024 , A61M5/30 , A61M2005/202 , A61M2202/0007 , A61M2202/30 , A61M2210/1042
摘要： Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface (e.g., a surface of a tissue of a subject). The self-righting articles described herein may comprise one or more tissue engaging surfaces configured to engage (e.g., interface with, inject into, anchor) with a surface (e.g., a surface of a tissue of a subject). In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent (e.g., for delivery of the active pharmaceutical agent to a location internal of the subject) such as a liquid pharmaceutical agent. In some cases, upon contact of the tissue with the tissue engaging surface of the article, the self-righting article may be configured to release one or more tissue interfacing components. In some cases, the tissue interfacing component is associated with a self-actuating component. For example, the self-righting article may comprise a self-actuating component configured, upon exposure to a fluid, to release the tissue interfacing component from the self-righting article.
-
公开(公告)号：US20200147179A1
公开(公告)日：2020-05-14
申请号：US16620363
申请日：2018-06-11
申请人： Novo Nordisk A/S
IPC分类号： A61K38/26 , A61K31/7034 , A61K31/19
摘要： The present invention relates to solid compositions for oral administration comprising (i) a GLP-1 derivative and the SGLT2 inhibitor dapagliflozin or (ii) a GLP-1 derivative and a salt of NAC in combination with an SGLT2 inhibitor.
-
公开(公告)号：US11622996B2
公开(公告)日：2023-04-11
申请号：US17053511
申请日：2019-05-06
申请人： Novo Nordisk A/S
发明人： Simon Bjerregaard , Ulrik Lytt Rahbek , Philip Jonas Sassene , Jorrit Jeroen Water , Andreas Vegge
摘要： The invention relates to pharmaceutical compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
-
公开(公告)号：US20220323544A1
公开(公告)日：2022-10-13
申请号：US17628697
申请日：2020-08-07
申请人： Novo Nordisk A/S
摘要： The invention relates to pharmaceutical compositions comprising a PCSK9 inhibitor, such as an EGF(A) peptide, and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
-
公开(公告)号：US20230000949A1
公开(公告)日：2023-01-05
申请号：US17773323
申请日：2020-11-06
申请人： Novo Nordisk A/S
发明人： Simon Bjerregaard , Ulrik Lytt Rahbek , Philip Jonas Sassene , Jorrit Jeroen Water , Andreas Vegge , Kaisa Naelapaeae
IPC分类号： A61K38/18 , A61K31/198 , A61K31/455 , A61K31/05 , A61K9/00 , A61K9/16
摘要： The invention relates to pharmaceutical compositions comprising a PCSK9 inhibitor, such as an EGF(A) peptide, and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
-
公开(公告)号：US20220265777A1
公开(公告)日：2022-08-25
申请号：US17628459
申请日：2020-08-06
申请人： Novo Nordisk A/S
发明人： Betty Lomstein Pedersen , Birgitte Nissen , Patrick William Garibay , Kaisa Naelapaeae , Andreas Vegge
IPC分类号： A61K38/26 , A61K9/20 , A61K9/00 , A61K31/351 , A61K31/381 , A61K31/7048 , A61K31/382 , A61K31/7056
摘要： The invention relates to solid pharmaceutical compositions comprising a GLP-1 agonist, an SGLT2 inhibitor and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
-
公开(公告)号：US20220016216A1
公开(公告)日：2022-01-20
申请号：US17496831
申请日：2021-10-08
申请人： Novo Nordisk A/S
IPC分类号： A61K38/26 , A61K31/19 , A61K31/7034
摘要： The present invention relates to solid compositions for oral administration comprising (i) a GLP-1 derivative and the SGLT2 inhibitor dapagliflozin or (ii) a GLP-1 derivative and a salt of NAC in combination with an SGLT2 inhibitor.
-
公开(公告)号：US20210236601A1
公开(公告)日：2021-08-05
申请号：US17053511
申请日：2019-05-06
申请人： Novo Nordisk A/S
发明人： Simon Bjerregaard , Ulrik Lytt Rahbek , Philip Jonas Sassene , Jorrit Jeroen Water , Andreas Vegge
摘要： The invention relates to pharmaceutical compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
-
公开(公告)号：US20220395559A1
公开(公告)日：2022-12-15
申请号：US17775034
申请日：2020-11-06
申请人： Novo Nordisk A/S
发明人： Kaisa Naelapaeae , Simon Bjerregaard , Ulrik Lytt Rahbek , Philip Jonas Sassene , Jorrit Jeroen Water , Andreas Vegge
IPC分类号： A61K38/26 , A61K31/166 , A61K31/455 , A61K31/05 , A61K45/06 , A61K31/7048 , A61K9/20
摘要： The invention relates to pharmaceutical compositions comprising a GLP-1 agonist, an SLGT2 inhibitor, a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, and a hydrotrope. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
-
公开(公告)号：US11167014B2
公开(公告)日：2021-11-09
申请号：US16620363
申请日：2018-06-11
申请人： Novo Nordisk A/S
IPC分类号： A61K38/00 , A61K38/26 , A61K31/19 , A61K31/7034
摘要： The present invention relates to solid compositions for oral administration comprising (i) a GLP-1 derivative and the SGLT2 inhibitor dapagliflozin or (ii) a GLP-1 derivative and a salt of NAC in combination with an SGLT2 inhibitor.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.032 秒)
